Skip to content
Screener

Royalty Pharma RPRX Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$167M-46.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
ALN
Alnylam PharmaceuticalsALNY
——
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——
Theravance Biopharma logo
Theravance BiopharmaTBPH
——
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
——

Other financials

Income statement

See full
Revenue$674.1M+16.5%
Operating income$133.1M-36.5%
Net income$17.9M-44.4%
EPS (diluted)$0.04-42.9%

Balance sheet

See full
Cash & equivalents$812.0M+28.5%
Total debt$9.0B+11.7%
Total equity$9.8B+3.1%
Total assets$19.8B+8.2%

Cash flow

See full
Operating cash flow$728.5M+100%

Valuation

See full
Market cap$25.6B+63.7%
Enterprise value$33.75B+46.5%
P/E31.4×+16.1×
P/S10.1×+3.3×

Profitability

See full
Operating margin59.6%-20.2pp
Net margin32.1%-12.3pp

Returns & leverage

See full
Return on equity8.5%-2.2pp
Debt / equity0.9×+0.1×
Current ratio2.8×+1.5×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:02 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001802768-26-000015
Line itemAs of June 30, 2026As of December 31, 2025
Current assets
Cash and cash equivalents$811,986$618,696
Financial royalty assets889,454854,386
Available for sale debt securities25,00018,800
Other royalty income receivable31,47429,316
Other current assets6,6566,893
Total current assets1,764,5701,528,091
Financial royalty assets, net16,192,71716,208,482

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Royalty Pharma's available for sale securities debt securities current?
Royalty Pharma (RPRX) reported available for sale securities debt securities current of $25M in Q2 2026.
How has Royalty Pharma's available for sale securities debt securities current changed year-over-year?
Royalty Pharma's available for sale securities debt securities current increased by 89.4% year-over-year, from $13.2M to $25M.
What is the long-term trend for Royalty Pharma's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Royalty Pharma's available for sale securities debt securities current has grown at a -23.1% compound annual growth rate (CAGR), from $69.98M to $18.8M.
What does available for sale securities debt securities current mean?
Available For Sale Securities Debt Securities Current

Ask your AI about Royalty Pharma's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude